Aegerion Pharma yanks $81M IPO
Bridgewater, N.J.’s Aegerion Pharmaceuticals withdrew an IPO that the company expected to raise as much as $80.5 million, citing “market conditions.” The company’s withdrawal statement is here. The company had filed to go public back in March.
Aegerion is developing drugs that lower cholesterol and trigyceride levels by limiting production of the substances in the liver. Like other specialty-pharmaceutical companies, the company doesn’t develop its own drugs, and instead acquires cast-offs from other companies. I wrote about its IPO plans here.
Next Story: Thoof, a news ranking site that wants to serve the masses
Previous Story: InCode BioPharmaceutics raises $2M to target autoimmunity
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
